Importantly, the use of an anti-OX40 agonist antibody has been shown to enhance T lymphocyte-mediated antitumor immunity and inhibit Treg induction in several cancer models, thereby promoting tumor regression and ameliorating patient survival [71, 72]. The gene discussed is TNFRSF4; the disease is cancer.